Associated with Dabur since the year 1998 , Dr . Singh is responsible for setting up the state of the art Molecular Biology Unit at DRF dedicated to new drug development from natural products and chemical libraries . Dr Anu leads the discovery & Preclinical teams , comprising of more than 80 scientists . Her team at DRF has domain expertise in preclinical biology and operates as drug discovery and development partner to global pharmaceutical and biotechnology companies .
Dr Singh has contributed to the successful development and global commercialization in the year 2007 of a nanoparticle based paclitaxel formulation viz Nanoxel TM for breast and ovarian cancers . She was involved in the successful development of a peptide based anticancer drug DRF7295 that was outlicensed to a European pharma major . She and her team have deep expertise in the repurposing of pharmaceutical compounds for new uses in underserved and unmet areas of healthcare . The most recent successful application has been to repurpose and benchmark compounds for the treatment or management of COVID 19 .
Dr Singh holds a doctorate degree in Endocrinology / Tumor Biology from All India
Institute of Medical Sciences ( AIIMS ), Delhi . She carried out her postdoctoral research at the National Institute of Immunology ( NII ) Delhi in the field of cell signaling in adenocarcinomas .
Dr Singh has been credited with 100 international patents and several more in India . She has published and presented more than 70 research papers in peer-reviewed journals & scientific meetings . She has active collaborations with academic institutions , and other research organizations and has trained more than 150 biotechnology post-graduates students . Dr . Singh holds memberships in several scientific committees and has presented her scientific contributions at several international and Indian meetings .
Current Position : Chief Operating Officer , Dabur Research Foundation
Impact : Successful development of a peptide based anticancer drug DRF7295 that was outlicensed to a European pharma major .
Alma Mater : National Institute of Immunology ( NII ); All India Institute of Medical Sciences ( AIIMS )
A technology enthusiast , Dr Singh feels that scientists should not lose the enormous research and the data that is very often seen in laboratory practices .
“ The data in the project is generated over years sometimes and it ’ s precious . And the versions that we change , the improvements that we do in our search for new molecules , the processes that we follow , the evolution over a period of time , very often gets lost because of the simple fact that it is stretched over a period of time . So it is likely that we need to use this electronic laboratory notebook system that is being talked about ,” says Dr Singh who in her free time likes to read , travel and stay connected with the grassroots of the society through socially relevant work .
BioTech
BIOVOICENEWS . COM 31